Overview
Neurology Regulatory Landscape
The regulatory environment for neurology therapies involves specialized requirements from FDA Division of Neurology Products, EMA CHMP Neurology Working Party, PMDA Neurology Review. This guide maps each requirement to ArcaScience's platform capabilities, demonstrating how AI-driven benefit-risk analysis aligns with and accelerates regulatory compliance.
Regulatory Requirements
Key Requirements by Agency
FDA Requirements
- ✓ Accelerated approval for neurodegenerative diseases
- ✓ Surrogate endpoint validation requirements
- ✓ REMS for CNS medications
- ✓ Suicidality assessment requirements (FDA Guidance)
- ✓ Post-marketing confirmatory trial requirements
EMA Requirements
- ✓ Conditional marketing authorization for neurodegeneration
- ✓ Guideline on clinical investigation of medicinal products for Alzheimer's disease
- ✓ Neurology-specific PSUR expectations
- ✓ Advanced therapy medicinal products (ATMPs) for neurological conditions
PMDA Requirements
- ✓ Japan-specific CNS safety monitoring
- ✓ Neurology conditional early approval
- ✓ Post-marketing surveillance for CNS therapies
ArcaScience Alignment
How ArcaScience Maps to Neurology Requirements
Data Coverage
Neurology-specific data from 47+ global sources, pre-harmonized and validated for regulatory submissions.
AI Models
Neurology-trained AI models for adverse event classification, signal detection, and benefit quantification with regulatory validation.
Regulatory Outputs
Pre-formatted outputs aligned with FDA Division of Neurology Products and EMA CHMP Neurology Working Party submission requirements.
Download
Get the Full Neurology Regulatory Landscape
Complete the form below to receive the document via email.
Related Resources